JP2000229815A - Liposomes and their use - Google Patents
Liposomes and their useInfo
- Publication number
- JP2000229815A JP2000229815A JP11028910A JP2891099A JP2000229815A JP 2000229815 A JP2000229815 A JP 2000229815A JP 11028910 A JP11028910 A JP 11028910A JP 2891099 A JP2891099 A JP 2891099A JP 2000229815 A JP2000229815 A JP 2000229815A
- Authority
- JP
- Japan
- Prior art keywords
- water
- liposome
- composition
- hair
- hair restorer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 114
- 229910001868 water Inorganic materials 0.000 claims abstract description 97
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 37
- 239000002537 cosmetic Substances 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 30
- 239000002245 particle Substances 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 239000013076 target substance Substances 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 150000003904 phospholipids Chemical class 0.000 claims description 18
- 239000002453 shampoo Substances 0.000 claims description 17
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- 239000000787 lecithin Substances 0.000 claims description 9
- 235000010445 lecithin Nutrition 0.000 claims description 9
- 229940067606 lecithin Drugs 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 5
- 239000010419 fine particle Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000003921 oil Substances 0.000 abstract description 13
- 230000003020 moisturizing effect Effects 0.000 abstract description 9
- 239000003925 fat Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 238000013268 sustained release Methods 0.000 abstract description 5
- 239000012730 sustained-release form Substances 0.000 abstract description 5
- -1 elixirs Substances 0.000 description 19
- 239000008213 purified water Substances 0.000 description 17
- 239000004094 surface-active agent Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000006071 cream Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000000919 ceramic Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003974 emollient agent Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940098465 tincture Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 235000017788 Cydonia oblonga Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940049964 oleate Drugs 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000010696 ester oil Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000008278 cosmetic cream Substances 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000003676 hair preparation Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000003752 hydrotrope Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- ZNVKGUVDRSSWHV-UHFFFAOYSA-L zinc;4-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 ZNVKGUVDRSSWHV-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ZFSXZJXLKAJIGS-UHFFFAOYSA-N halocarban Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=CC(Cl)=CC=2)=C1 ZFSXZJXLKAJIGS-UHFFFAOYSA-N 0.000 description 1
- 229950006625 halocarban Drugs 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 229940066293 respiratory stimulants Drugs 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940077386 sodium benzenesulfonate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Water Treatment By Electricity Or Magnetism (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
(57)【要約】
【課題】 粒径の小さなリポソームを提供すること。
【解決手段】 17O−NMRシグナルの半値幅が9
0Hz以下の水と目的物質と両親媒性化合物とを超高圧
ホモジナイザー処理して得られる。リポソーム内に薬
剤、化粧品、育毛剤または養毛剤を含有させた組成物
は、組織への親和性に優れるため、薬剤、保湿成分、育
毛成分、あるいは養毛成分等が組織に付着、進入しやす
くなり、徐放性とあいまって、高い効果が期待できる。
特に、半値幅が60Hz以下の水を用いた場合、油脂類
を通常の水の1.5倍以上も分散させる能力を有するこ
とから、リポソーム内に、より多量の医薬、化粧料、育
毛剤あるいは養毛剤を保持することができるので、さら
に高い効果が期待できる。(57) [Problem] To provide a liposome having a small particle size. SOLUTION: The half-value width of the 17 O-NMR signal is 9
Obtained by subjecting water at 0 Hz or lower, a target substance, and an amphipathic compound to an ultrahigh-pressure homogenizer treatment. Since a composition containing a drug, cosmetics, a hair restorer or a hair restorer in the liposome has an excellent affinity for the tissue, the drug, a moisturizing component, a hair restorer, or a hair restorer can easily adhere to and enter the tissue. High efficacy can be expected in combination with sustained release.
In particular, when water having a half width of 60 Hz or less is used, since it has an ability to disperse fats and oils 1.5 times or more of ordinary water, a larger amount of medicine, cosmetics, hair restorer or Since the hair restorer can be maintained, a higher effect can be expected.
Description
【0001】[0001]
【発明の属する技術分野】本発明は、微小な粒径を有す
るリポソーム、その製法、並びにこのリポソームを含有
する組成物に関する。さらに、詳しくは、本発明は、特
定の17O−NMRシグナルの半値幅を有する水と目的
物質とリン脂質とを混合して得られるリポソームであっ
て、その平均粒径が通常の水を用いて製造されたリポソ
ームの平均粒径よりも小さいリポソームに関する。The present invention relates to a liposome having a small particle size, a method for producing the liposome, and a composition containing the liposome. More specifically, the present invention relates to a liposome obtained by mixing water having a half-width of a specific 17 O-NMR signal, a target substance, and a phospholipid, the average particle diameter of which is determined using normal water. Liposomes smaller than the average particle size of the liposomes produced by the method.
【0002】[0002]
【従来の技術】一般的に、リポソームは、リン脂質と水
とを混合して得られる脂質の単層または複数層からなる
閉鎖小胞であり、内部の水層あるいは脂質層に種々の物
質を保持できるので、その有用性は大きい。例えば、医
薬品を包み込んだリポソームはドラッグデリバリーシス
テム(DDS)に用いられる。この場合、リポソームと
しては、粒径が小さいほど、同じ濃度でも比表面積が大
きくなり、組織との親和性も大きくなるので、好都合で
ある。2. Description of the Related Art Generally, a liposome is a closed vesicle composed of a monolayer or a plurality of layers of a lipid obtained by mixing a phospholipid and water, and various substances are added to an inner aqueous layer or a lipid layer. Its usefulness is great because it can be retained. For example, a liposome enclosing a drug is used in a drug delivery system (DDS). In this case, the smaller the particle size of the liposome, the larger the specific surface area even at the same concentration, and the greater the affinity with the tissue, which is advantageous.
【0003】リポソームの作製技術は急速に進歩してお
り、粒径が小さいリポソームの作製がなされている。し
かし、従来のリポソームを小さくする技術は物理的方法
に関するものであり、ほぼ、完成の域にある。しかしな
がら、リポソームの構成物質に着目して、粒径を小さく
する試みはなされていないのが現状である。[0003] The technology for producing liposomes is rapidly advancing, and liposomes having a small particle size are being produced. However, the conventional techniques for reducing liposomes are related to physical methods and are almost in a state of completion. However, at present, no attempt has been made to reduce the particle size by focusing on the constituents of the liposome.
【0004】[0004]
【発明が解決しようとする課題】そこで、本発明者ら
は、リポソームの粒径を小さくするためにリポソームを
構成する成分、特に水に着目して鋭意研究を進めた結
果、特定の17O−NMRシグナルの半値幅を有する水
を用いて得られたリポソームの平均粒径は、通常の水を
用いた場合よりも大幅に低下することを見出し、本発明
に到達した。[SUMMARY OF THE INVENTION Therefore, the present inventors have found that components constituting the liposome in order to reduce the particle size of the liposomes, result of our intensive studies with particular attention to the water, the specific 17 O- The present inventors have found that the average particle size of liposomes obtained using water having a half-width of the NMR signal is significantly lower than that obtained using ordinary water, and arrived at the present invention.
【0005】[0005]
【課題を解決するための手段】本発明は、17O−NM
Rシグナルの半値幅が90Hz以下の水と目的物質と両
親媒性化合物とを混合して得られる微小な粒径を有する
リポソームであって、該リポソームの平均粒径が、通常
の水を用いて製造されたリポソームの平均粒径よりも小
さいリポソームに関する。The present invention provides a 17 O-NM.
A liposome having a small particle diameter obtained by mixing water having a half width of an R signal of 90 Hz or less, a target substance, and an amphipathic compound, wherein the average particle diameter of the liposome is determined using ordinary water. It relates to liposomes smaller than the average particle size of the liposomes produced.
【0006】好適な実施態様においては、前記両親媒性
化合物がリン脂質であり、さらに好適な実施態様におい
ては、前記リン脂質がレシチンである。[0006] In a preferred embodiment, the amphiphilic compound is a phospholipid, and in a further preferred embodiment, the phospholipid is lecithin.
【0007】また、本発明は、17O−NMRシグナル
の半値幅が90Hz以下の水と目的成分と両親媒性化合
物とを混合する工程を含む、微小な粒径を有するリポソ
ームの製造方法に関する。The present invention also relates to a method for producing a liposome having a fine particle diameter, which comprises a step of mixing water having a half-width of 17 O-NMR signal of 90 Hz or less, a target component and an amphiphilic compound.
【0008】好適な実施態様においては、前記水の17
O−NMRシグナルの半値幅が60Hz以下である。[0008] In a preferred embodiment, the water 17
The half width of the O-NMR signal is 60 Hz or less.
【0009】また、好適な実施態様においては、前記水
が純水を磁化処理して得られた水である。In a preferred embodiment, the water is water obtained by magnetizing pure water.
【0010】好適な実施態様においては、前記両親媒性
化合物がリン脂質であり、さらに好適な実施態様におい
ては、前記リン脂質がレシチンである。[0010] In a preferred embodiment, the amphiphilic compound is a phospholipid, and in a further preferred embodiment, the phospholipid is lecithin.
【0011】さらに、本発明は17O−NMRシグナル
の半値幅が90Hz以下の水と目的物質と両親媒性化合
物とを混合して得られる微小な粒径を有するリポソーム
を含有する組成物に関する。Further, the present invention relates to a composition containing liposomes having a small particle diameter obtained by mixing water having a half-width of 17 O-NMR signal of 90 Hz or less, a target substance and an amphiphilic compound.
【0012】好適な実施態様においては、前記両親媒性
化合物がリン脂質であり、さらに好適な実施態様におい
ては、前記リン脂質がレシチンである。[0012] In a preferred embodiment, the amphipathic compound is a phospholipid, and in a further preferred embodiment, the phospholipid is lecithin.
【0013】好適な実施態様においては、前記目的物質
が薬剤、化粧品、育毛剤または養毛剤であり、前記組成
物が医薬組成物、化粧品組成物、育毛組成物または養毛
組成物である。[0013] In a preferred embodiment, the target substance is a drug, a cosmetic, a hair restorer or a hair restorer, and the composition is a pharmaceutical composition, a cosmetic composition, a hair restorer or a hair restorer.
【0014】さらに好適な実施態様においては、前記化
粧品組成物が、化粧クリーム、化粧水、乳液、美容液、
ファンデーション、シャンプー、リンス、トリートメン
トまたは整髪料である。In a further preferred embodiment, the cosmetic composition is a cosmetic cream, a lotion, an emulsion, a serum,
It is a foundation, shampoo, rinse, treatment or hair styling.
【0015】より好適な実施態様においては、前記シャ
ンプー、リンス、トリートメントまたは整髪料が養毛成
分及び/又は育毛成分を含んでいる。[0015] In a more preferred embodiment, the shampoo, rinse, treatment or hair styling contains a hair restoration component and / or a hair restoration component.
【0016】また、好適な実施態様においては、前記医
薬組成物が、経口投与、粘膜適用、体表適用および血管
内または組織内投与の投与・適用形態に適合した組成物
である。In a preferred embodiment, the pharmaceutical composition is a composition suitable for oral administration, mucosal application, body surface application, and intravascular or tissue administration.
【0017】[0017]
【発明の実施の形態】本発明に用いられる、17O−N
MRシグナルの半値幅(以下、単に半値幅ということが
ある)が90Hz以下の水は、水のクラスターを小さく
することによって得られる。水は、水素2個と酸素1個
とからなる分子が分子間に働く電気的な力(酸素と水素
間の水素結合)により分子集団を形成している。クラス
ターとはこの水の分子集団のことをいう。水のクラスタ
ーの生成度合いは、17O−NMRシグナルの半値幅で
測定することができ、半値幅が小さいと、クラスターも
小さい。従って、本発明の水の半値幅は、小さいほど好
ましく、より好ましくは75Hz以下、さらに好ましく
は、60Hz以下である。BEST MODE FOR CARRYING OUT THE INVENTION 17 O-N used in the present invention
Water having a half width of the MR signal (hereinafter sometimes simply referred to as a half width) of 90 Hz or less can be obtained by reducing the cluster of water. Water forms a molecular group by an electric force (hydrogen bond between oxygen and hydrogen) that acts between molecules of two hydrogens and one oxygen. A cluster refers to this molecular group of water. The degree of formation of water clusters can be measured by the half-width of the 17 O-NMR signal, and the smaller the half-width, the smaller the cluster. Therefore, the half width of water of the present invention is preferably as small as possible, more preferably 75 Hz or less, and further preferably 60 Hz or less.
【0018】本発明に使用する17O−NMRシグナル
の半値幅が90Hz以下の水は、純水、日本薬局方にい
う精製水、水道水、イオン交換水等の水を、磁力線処
理、微弱電流処理、電場処理、セラミック板処理、遠赤
外線処理、高周波(電磁波)処理、機械的処理、超音波
処理、起電力処理、レーザー光線処理、または天然鉱石
処理を、単独であるいは組合せて行うことにより、得ら
れる。Water having a half-value width of 90 Hz or less of 17 O-NMR signal used in the present invention is obtained by treating pure water, purified water, tap water, ion-exchanged water and the like as described in the Japanese Pharmacopoeia by magnetic line treatment, weak current. Treatment, electric field treatment, ceramic plate treatment, far infrared treatment, high frequency (electromagnetic wave) treatment, mechanical treatment, ultrasonic treatment, electromotive force treatment, laser beam treatment, or natural ore treatment, singly or in combination. Can be
【0019】使用される水は、好ましくは、精製水、イ
オン交換水、純水であり、最も好ましくは、純水であ
る。なお、純水とは、通常の水を脱塩して得られる純粋
の水に近い水をいい、電気抵抗値で50Ω・cm程度以上
の比抵抗を有するものをいう。超純水も含む。The water used is preferably purified water, ion-exchanged water or pure water, and most preferably pure water. Note that pure water refers to water that is close to pure water obtained by desalting ordinary water and has a specific resistance of about 50 Ω · cm or more in electrical resistance. Including ultrapure water.
【0020】純水をクラスター処理して得られた水は、
半値幅が60Hz以下になるばかりでなく、油脂類を通
常の水の1.5倍以上も分散させる能力を有することか
ら、リポソームの粒径を小さくするのみならず、リポソ
ーム内に、より多量の薬剤、養毛成分などの目的物を保
持することができる点でも、優れている。The water obtained by clustering pure water is
Not only does the half width become 60 Hz or less, but also it has the ability to disperse fats and oils 1.5 times or more in ordinary water. It is also excellent in that it can hold a target substance such as a drug and a hair-growing component.
【0021】水の半値幅を90Hz以下にする処理方法
を、以下、磁力線処理方法を例にとって、簡単に説明す
る。磁力線処理は、通常、0.07T(テスラ:1テス
ラは10,000ガウス)程度以上の磁界強度を有する
磁石(マグネット装置)の間隙に、水を一定の流速以上
で通過させて行う。0.3T以上の磁力線で処理するこ
とが好ましい。特に1.2T以上が好ましい。磁力線処
理装置および磁力線処理水の製造方法は、例えば、特開
平8−197064号公報に記載されている。A processing method for reducing the half width of water to 90 Hz or less will be briefly described below by taking a magnetic field line processing method as an example. The line of magnetic force processing is usually performed by passing water at a fixed flow rate or higher through a gap between magnets (magnet devices) having a magnetic field strength of about 0.07 T (Tesla: 10,000 Gauss) or more. The treatment is preferably performed with a line of magnetic force of 0.3 T or more. In particular, 1.2T or more is preferable. A magnetic field line treatment apparatus and a method for producing magnetic field line treated water are described in, for example, Japanese Patent Application Laid-Open No. 8-1970064.
【0022】微弱電流処理は、絶縁されない内部電極と
外部電極との空隙に水を流し、数十ミリアンペアの微弱
電流を流して行う。The weak current treatment is performed by flowing water into the gap between the non-insulated internal electrode and the external electrode and passing a weak current of several tens of milliamps.
【0023】電場処理は、水槽内の水に1,000ボル
ト以上の直流もしくは交流電圧をかけて行う。電気伝導
度をあげるために、例えば、木炭等を浸漬させ得る。The electric field treatment is performed by applying a DC or AC voltage of 1,000 volts or more to the water in the water tank. In order to increase the electric conductivity, for example, charcoal or the like can be immersed.
【0024】セラミック板処理は、波長が6〜14μm
の遠赤外線を放射する素材で作製されたセラミック板を
水槽内に浸漬させる方法である。The wavelength of the ceramic plate treatment is 6 to 14 μm.
In this method, a ceramic plate made of a material emitting far infrared rays is immersed in a water tank.
【0025】遠赤外線処理には、遠赤外線を放射するセ
ラミックフィルターを通過させる方法、あるいは遠赤外
線ヒーターからの出力を水にあてる方法がある。セラミ
ックフィルターを通過させる方法は、セラミック板処理
とほぼ同じ原理である。The far-infrared treatment includes a method of passing through a ceramic filter that emits far-infrared rays, and a method of applying the output from a far-infrared heater to water. The method of passing through a ceramic filter is almost the same as that of the ceramic plate processing.
【0026】高周波(電磁波)処理は、超音波よりも高
い周波数を水にあてる方法である。電子レンジのような
マイクロ波処理が該当する。The high frequency (electromagnetic wave) processing is a method in which a higher frequency than ultrasonic waves is applied to water. Microwave processing such as a microwave oven is applicable.
【0027】機械的処理は、水を高速で回転させる方法
である。The mechanical treatment is a method of rotating water at high speed.
【0028】超音波処理は、20〜40KHz程度の周
波数の超音波を水にあてる方法である。宝石あるいはガ
ラス器具の洗浄に利用する高出力のものと、酒の熟成を
促進させる微弱な出力のもののいずれをが、使用でき
る。The ultrasonic treatment is a method of applying ultrasonic waves having a frequency of about 20 to 40 KHz to water. Either a high output used for cleaning jewelry or glass utensils or a low output which promotes aging of sake can be used.
【0029】起電力処理は導電性の異種材料間に水を流
し、そのイオン化電圧差で水のクラスターを小さくする
方法である。The electromotive force treatment is a method in which water flows between different kinds of conductive materials, and the clusters of water are reduced by the difference in ionization voltage.
【0030】天然鉱石処理は、積層した天然の鉱石層を
適切な圧力で水を通過させてクラスターを小さくする方
法である。[0030] Natural ore treatment is a method of passing clusters of natural ore layers at a suitable pressure through water to reduce clusters.
【0031】レーザー光線処理は、レーザー光線を発振
する種々の媒体を用いて行い得る。例えば、気体レーザ
ー(H2の109.8nmから重クロロホルム(CDC1
3)の1990.75μm)、液体レーザー、固体レー
ザー(YAGレーザー、ガラスレーザー、ルビーレーザ
ー等)を照射して水を処理する。The laser beam treatment can be performed using various media that emit a laser beam. For example, a gas laser (H2O from 109.8 nm to deuterated chloroform (CDC1
3) (1990.75 μm), a liquid laser or a solid laser (YAG laser, glass laser, ruby laser, etc.) is irradiated to treat water.
【0032】本明細書において、リポソームとは、いわ
ゆる天然のリン脂質を用いて作製されるリポソームの他
にも、両親媒性化合物を用いて形成されるベシクルを含
む広い概念を意味する。In the present specification, the term “liposome” refers to a broad concept including liposomes prepared using so-called natural phospholipids and vesicles formed using an amphipathic compound.
【0033】リポソームの製造に用いられる両親媒性化
合物は、1分子中に親水基と疎水基とを有する化合物で
ある。例えば、「機能性界面活性剤の開発技術」(株式
会社CMC(1998))の19-26頁に記載されているような
アニオン系ベシクル形成界面活性剤、両性系ベシクル形
成界面活性剤、非イオン系ベシクル形成界面活性剤、天
然系ベシクル形成界面活性剤等が挙げられる。The amphipathic compound used for producing the liposome is a compound having a hydrophilic group and a hydrophobic group in one molecule. For example, anionic vesicle-forming surfactants, amphoteric vesicle-forming surfactants, and non-ionic vesicle-forming surfactants described on pages 19-26 of "Development Technology of Functional Surfactants" (CMC (1998)). Vesicle-forming surfactants and natural vesicle-forming surfactants.
【0034】これらの中で、天然系ベシクル形成界面活
性剤が、安全性等の観点から好ましい。天然系ベシクル
形成界面活性剤としては、グリセリド系、糖脂質系、ア
ミノ酸系、ステロイド系およびリン脂質系が好適に用い
られる。Among these, natural vesicle-forming surfactants are preferred from the viewpoint of safety and the like. As the natural vesicle-forming surfactant, glycerides, glycolipids, amino acids, steroids and phospholipids are preferably used.
【0035】そして、リン脂質系が最も好適に用いられ
る。リン脂質としては、レシチン(ホスファチジルコリ
ン)、ホスファチジルエタノールアミン、ホスファチジ
ルセリン、ホスファチジルイノシトール、ジホスファチ
ジルグリセロール、ホスファチジン酸、スフィンゴミエ
リン等が挙げられる。また、これらのリン脂質を含有す
る組成物も好適に用いられる。[0035] Phospholipids are most preferably used. Examples of the phospholipid include lecithin (phosphatidylcholine), phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, diphosphatidylglycerol, phosphatidic acid, sphingomyelin and the like. Compositions containing these phospholipids are also preferably used.
【0036】なお、リポソーム膜、特にレシチン膜の補
強、安定成分としてコレステロールを含んでいてもよ
い。The liposome membrane, particularly lecithin membrane, may contain cholesterol as a reinforcing and stabilizing component.
【0037】本発明のリポソームは、一般的には、半値
幅が90Hz以下の水に、適量の目的物質と約0.01
重量%〜約20重量%、好ましくは約0.1重量%〜約
5重量%の両親媒性化合物とを混合して、分散させ、つ
いで、高圧ホモジナイザー、超高圧ホモジナイザー等で
処理することにより得られる。The liposome of the present invention is generally prepared by adding an appropriate amount of the target substance to water having a half width of 90 Hz or less in an amount of about 0.01.
% To about 20% by weight, preferably about 0.1% to about 5% by weight of an amphipathic compound, mixed and dispersed, and then treated with a high-pressure homogenizer, an ultra-high-pressure homogenizer or the like. Can be
【0038】リポソームはできるだけ小さいほうが好ま
しいため、超高圧ホモジナイザーが好適に用いられる。
例えば、マイクロフルイダイザー(みずほ工業(株)
製)を用いると、微粒子のリポソームが作製される。Since it is preferable that the liposome is as small as possible, an ultrahigh pressure homogenizer is suitably used.
For example, a microfluidizer (Mizuho Industry Co., Ltd.)
Is used to produce fine liposomes.
【0039】通常は、複数層のリポソームが得られる
が、これをさらに、超音波処理等することにより、単層
のリポソームとすることもできる。従って、本発明のリ
ポソームには、単層および複数層のリポソームが含まれ
る。Usually, a multi-layered liposome is obtained, but it can be converted into a mono-layered liposome by further sonication. Thus, the liposomes of the present invention include monolayer and multi-layer liposomes.
【0040】本発明のリポソームは、半値幅が90Hz
以上の水を用いた場合に比べて、平均粒径が小さい。特
に、半値幅が60Hz以下の水を用いた場合には、平均
粒径は約1/2程度になる。従って、従来の水で作製さ
れたリポソームに比べて、同じ濃度でも比表面積が大き
くなるため、反応性が増大し、生体に適用したときには
組織への親和性が増大する。従って、本発明のリポソー
ムは、界面活性剤が利用されるあらゆる分野に使用され
る。The liposome of the present invention has a half width of 90 Hz.
The average particle size is smaller than when the above water is used. In particular, when water having a half width of 60 Hz or less is used, the average particle size becomes about 1/2. Accordingly, the specific surface area is increased even at the same concentration as compared with conventional liposomes made of water, so that the reactivity is increased, and when applied to a living body, the affinity for tissue is increased. Therefore, the liposome of the present invention is used in any field where a surfactant is used.
【0041】本発明のリポソームに含ませることができ
る目的物質としては、好適には、医薬品、化粧品、育毛
剤、養毛剤等が挙げられる。そして、医薬品、化粧品、
育毛剤、または養毛剤を含むリポソームは、それぞれの
組成物として適切な物質と混合され、医薬組成物、化粧
品組成物、育毛剤組成物、養毛剤組成物とされる。The target substance which can be contained in the liposome of the present invention is preferably a drug, cosmetic, hair restorer, hair restorer, or the like. And pharmaceuticals, cosmetics,
The hair restorer or the liposome containing the hair restorer is mixed with a substance suitable as each composition to obtain a pharmaceutical composition, a cosmetic composition, a hair restorer composition, and a hair restorer composition.
【0042】医薬組成物としては、経口投与(胃腸
管)、粘膜適用(眼、口腔粘膜、咽喉、鼻腔、気管支・
肺、腸、下部体腔)、体表適用(皮膚、体腔・外傷面)
および血管内または組織内投与(静脈内、筋肉内、およ
び皮下)の投与・適用形態に適合した組成物が挙げられ
る。Pharmaceutical compositions include oral administration (gastrointestinal tract), mucosal application (eye, oral mucosa, throat, nasal cavity, bronchial
Lung, intestine, lower body cavity), body surface application (skin, body cavity / trauma surface)
And compositions adapted for intravascular or intravenous (intravenous, intramuscular, and subcutaneous) administration and application forms.
【0043】これらの組成物が、例えば、経口投与、注
射等の方法で投与あるいは適用されると、従来のリポソ
ームよりも小さい粒径であるため、リポソームは体内へ
より速く吸収され、標的器官や組織の周囲に高濃度の医
薬品を伝達でき、徐放性とあいまって、高い薬理効果が
期待できる。特に、半値幅が60Hz以下の水を用いた
場合、上記のように、油脂類を通常の水の1.5倍以上
も分散させる能力を有することから、リポソーム内に、
より多量の薬剤を保持することができるので、さらに高
い薬理効果が期待できる。When these compositions are administered or applied, for example, by oral administration, injection, or the like, the liposomes are absorbed into the body more quickly because they have a smaller particle size than conventional liposomes, and can be used as a target organ or target. A high concentration of drug can be transmitted around the tissue, and a high pharmacological effect can be expected in combination with sustained release. In particular, when water having a half width of 60 Hz or less is used, as described above, since it has the ability to disperse fats and oils 1.5 times or more in normal water,
Since a larger amount of drug can be held, a higher pharmacological effect can be expected.
【0044】経口投与に適した剤形としては、散剤、顆
粒剤、内服錠、カプセル剤、丸剤、エルキシル剤、シロ
ップ剤、リモナーデ剤、芳香水剤、乳剤、懸濁剤、浸
剤、煎剤、内用チンキ剤、エキス剤、流エキス剤が挙げ
られる。The dosage forms suitable for oral administration include powders, granules, oral tablets, capsules, pills, elixirs, syrups, limonades, fragrances, emulsions, suspensions, infusions, decoctions, An internal tincture, an extract and a fluid extract may be mentioned.
【0045】粘膜適用に適した剤形としては、眼の場合
は点眼剤あるいは眼軟膏剤等、口腔粘膜の場合は、舌下
剤、バッカル錠およびトローチ剤等、咽喉の場合は含そ
う剤、鼻腔の場合はスプレー剤、気管支・肺の場合はエ
アゾール剤および吸入剤等、腸の場合は浣腸剤等、下部
体腔の場合は坐剤および腟剤等が挙げられる。[0045] Dosage forms suitable for mucosal application include eye drops or ointments for the eye, sublinguals, buccal tablets and lozenges for the oral mucosa, mouthwashes for the throat, nasal cavity Examples include sprays, aerosols and inhalants for bronchi and lungs, enemas for the intestine, and suppositories and vaginals for the lower body cavity.
【0046】体表適用に適した剤形としては、皮膚の場
合は、軟膏剤、硬膏剤、リニメント剤、ローション剤、
パスタ剤、パップ剤、液剤、酒精剤、および外用チンキ
剤等が挙げられる。また、体腔・外傷面の場合は、潅注
剤等が挙げられる。As the dosage form suitable for application to the body surface, in the case of skin, ointments, plasters, liniments, lotions,
Pasta, poultice, liquid, alcoholic beverage, external tincture and the like can be mentioned. In the case of a body cavity / trauma surface, an irrigation agent and the like can be mentioned.
【0047】血管内投与または組織内投与に適した剤形
として、皮下、筋肉内、静脈内等および皮下組織の場合
は注射剤、皮下組織の場合は植込剤等が用いられ得る。As dosage forms suitable for intravascular or intradermal administration, injections can be used for subcutaneous, intramuscular, intravenous, etc. and subcutaneous tissues, and implants for subcutaneous tissues.
【0048】上記剤形を形成するために、通常、医薬品
の製造に用いられる賦形剤、補助剤、および添加剤等が
添加され得る。In order to form the above-mentioned dosage form, excipients, auxiliaries, additives and the like usually used in the production of pharmaceuticals can be added.
【0049】賦形剤としては、溶剤、基剤、希釈剤、増
量剤、充填剤、補形剤等が挙げられる。Examples of the excipient include solvents, bases, diluents, extenders, fillers, excipients and the like.
【0050】補助剤としては、溶解補助剤、可溶化剤、
緩衝剤、等張化剤、乳化剤、懸濁化剤、分散剤、増粘
剤、ゲル化剤、硬化剤、吸収剤、粘着剤、弾性剤、可塑
剤、結合剤、崩壊剤、滑沢剤、コーティング剤、徐放化
剤、および噴射剤等が挙げられる。As the auxiliary agent, a solubilizing agent, a solubilizing agent,
Buffers, tonicity agents, emulsifiers, suspending agents, dispersants, thickeners, gelling agents, hardeners, absorbents, adhesives, elasticizers, plasticizers, binders, disintegrants, lubricants , A coating agent, a sustained release agent, and a propellant.
【0051】添加剤としては、抗酸化剤、保存剤、保湿
剤、遮光剤、光沢剤、帯電防止剤、芳香剤、甘味剤、着
香剤、着色剤、緩和剤、および無痛化剤等が挙げられ
る。The additives include antioxidants, preservatives, humectants, light-shielding agents, brighteners, antistatic agents, fragrances, sweeteners, flavoring agents, coloring agents, soothing agents, and soothing agents. No.
【0052】本発明の医薬組成物に適した薬剤として
は、例えば、強心剤、昇圧剤、抗不整脈剤、狭心症治療
剤、血管拡張剤、降圧剤、利尿剤および抗高脂血症剤等
の循環器系の薬剤、気管支拡張剤、呼吸促進剤、気管支
喘息治療剤、鎮咳剤および去痰剤等の呼吸器系の薬剤、
健胃消化剤、消化性潰瘍治療剤、整腸止痢剤、下剤、大
腸症治療剤、痔疾治療剤等の消化器系の薬剤、肝臓ある
いは膵臓疾患治療剤、解毒剤、利胆剤等の肝臓・膵臓・
胆嚢疾患治療剤、腎臓疾患治療剤等の泌尿器・生殖器に
作用する薬剤、睡眠剤、鎮静剤、解熱鎮痛剤、抗てんか
ん剤、向精神剤、脳代謝賦活剤、自律神経作用剤、パー
キンソン病治療剤、筋弛緩剤等の神経系に作用する薬
剤、造血剤、止血剤、抗血栓剤等の血液系の薬剤、副腎
皮質ステロイド剤、非ステロイド抗炎症剤、消炎酵素
剤、抗リウマチ剤、抗ヒスタミン剤等の炎症・アレルギ
ーに作用する薬剤、糖尿病治療剤および痛風治療剤等の
代謝系に作用する薬剤、病原微生物に対する薬剤、眼科
用、耳鼻科用および皮膚科用の感覚器官の薬剤、免疫抑
制剤、骨代謝改善剤、ホルモン剤、ビタミン剤、および
漢方薬等が挙げられる。[0051] Drugs suitable for the pharmaceutical composition of the present invention include, for example, inotropic agents, vasopressors, antiarrhythmic agents, therapeutic agents for angina pectoris, vasodilators, antihypertensive agents, diuretics and antihyperlipidemic agents. Respiratory drugs, such as cardiovascular drugs, bronchodilators, respiratory stimulants, bronchial asthma treatments, antitussives and expectorants
Gastrointestinal drugs such as stomachic digestives, peptic ulcer treatments, intestinal antidiarrheals, laxatives, treatment for colitis, treatment for hemorrhoids, treatment for liver or pancreatic diseases, antidote, bile medicine, etc. Liver, pancreas,
Urinary and reproductive agents such as gallbladder and renal disease drugs, sleeping pills, sedatives, antipyretic analgesics, antiepileptics, psychotropic drugs, cerebral metabolic activators, autonomic nervous drugs, Parkinson's disease treatment Agents acting on the nervous system, such as drugs, muscle relaxants, hematopoietic agents, hemostatic agents, blood system agents such as antithrombotic agents, corticosteroids, nonsteroidal anti-inflammatory agents, anti-inflammatory enzymes, antirheumatic agents, antihistamines Drugs that act on metabolic systems such as drugs for treating inflammation and allergies, such as drugs for treating diabetes and gout, drugs for pathogenic microorganisms, drugs for sensory organs for ophthalmology, otolaryngology and dermatology, and immunosuppressants , A bone metabolism improving agent, a hormonal agent, a vitamin agent, a Chinese medicine and the like.
【0053】なお、医薬組成物の剤形は、当業者に公知
の方法で、目的に応じて形成される。The dosage form of the pharmaceutical composition is formed according to the purpose by a method known to those skilled in the art.
【0054】また、本発明の平均粒径の小さいリポソー
ムを化粧品組成物、育毛剤組成物、あるいは養毛剤組成
物に用いた場合にも、リポソームの皮膚あるいは毛髪組
織への親和性が高くなるため、リポソームに含有される
成分、例えば、保湿成分、育毛成分、養毛成分等が皮膚
角質層、毛髪等に付着、進入しやすくなり、徐放性とあ
いまって、高い効果が期待できる。特に、半値幅が60
Hz以下の水を用いた場合、上記のように、油脂類を通
常の水の1.5倍以上も分散させる能力を有することか
ら、リポソーム内に、より多量の化粧料、育毛剤あるい
は養毛剤を保持することができるので、さらに高い効果
が期待できる。Further, when the liposome having a small average particle size of the present invention is used in a cosmetic composition, a hair restorer composition or a hair restorer composition, the affinity of the liposome to the skin or hair tissue is increased. Components contained in the liposome, for example, moisturizing components, hair-growing components, hair-growing components, and the like can easily adhere to and enter the stratum corneum, hair, and the like, and can be expected to have a high effect in combination with sustained release. In particular, the half width is 60
When water at a frequency of less than or equal to Hz is used, as described above, since it has the ability to disperse fats and oils 1.5 times or more than ordinary water, a larger amount of cosmetics, hair restorer or hair restorer is contained in the liposome. Since it can be maintained, higher effects can be expected.
【0055】化粧品組成物としては、基礎化粧品(化粧
水、クリーム、乳液、美容液、パック等)、仕上げ化粧
品(ファンデーション、口紅、頬紅、おしろい等)、頭
髪用化粧料としてはシャンプー、リンス、トリートメン
トまたは整髪料が挙げられる。シャンプー、リンス、ト
リートメントまたは整髪料に養毛成分あるいは育毛成分
が含まれていてもよい。As cosmetic compositions, basic cosmetics (lotion, cream, milky lotion, serum, pack, etc.), finished cosmetics (foundation, lipstick, blusher, whitening, etc.), and shampoos, rinses, treatments as hair cosmetics Or a hairdressing agent. A shampoo, a rinse, a treatment or a hairdressing material may contain a hair-growing component or a hair-growing component.
【0056】基礎化粧品としては、通常、化粧料として
配合される水性成分、油性成分及び/またはその他の各
種成分を含むリポソームを分散した化粧品でも良く、あ
るいは、上記リポソームと通常化粧料として配合される
油性成分、水性成分、乳化剤等の各種成分が配合された
化粧品であってもよい。The basic cosmetic may be a cosmetic in which a liposome containing an aqueous component, an oily component and / or other various components, which is usually blended as a cosmetic, is dispersed, or is blended with the liposome as a usual cosmetic. It may be a cosmetic containing various components such as an oil component, an aqueous component, and an emulsifier.
【0057】水性成分としては、例えば、保湿剤、粘液
剤、アルコール等が挙げられる。Examples of the aqueous component include a humectant, a mucous agent, an alcohol and the like.
【0058】保湿剤は、角質層の保湿、使用感等に寄与
し、具体的には、例えば、グリセリン、プロピレングリ
コール、ジプロピレングリコール、1,3−ブチレング
リコール、ポリエチレングリコール、多価アルコール、
糖類、アミノ酸類等が挙げられる。これらの保湿剤は、
通常約20重量%、好ましくは約15重量%より少ない
量添加される。The humectant contributes to the moisturizing of the stratum corneum, a feeling of use, and the like. Specifically, for example, glycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol, polyethylene glycol, polyhydric alcohol,
Sugars, amino acids and the like can be mentioned. These moisturizers
Usually it is added in an amount of less than about 20% by weight, preferably less than about 15% by weight.
【0059】粘液剤(増粘剤)は、保湿性、安定性、使
用感等に寄与し、具体的には、例えば、クインスシート
(クインスシードゴム)、トラガントガム、ペクチン、
アルギン酸塩、セルロース誘導体(例えば、カルボキシ
メチルセルロースナトリウム)、アクリル酸系ポリマ
ー、ビーガム、ポリビニルアルコール等が挙げられる。The mucus (thickening agent) contributes to moisturizing properties, stability, feeling of use, etc. Specifically, for example, quince sheet (quince seed gum), tragacanth gum, pectin,
Alginates, cellulose derivatives (for example, sodium carboxymethylcellulose), acrylic acid-based polymers, veegum, polyvinyl alcohol and the like can be mentioned.
【0060】アルコールは、清涼感、殺菌、配合成分の
溶解等に寄与し、例えば、エタノール、イソプロパノー
ル等が挙げられる。Alcohol contributes to refreshing feeling, sterilization, dissolution of the components, and the like, and examples thereof include ethanol and isopropanol.
【0061】油性成分としては、動植物系、鉱物系の天
然の油性成分および合成の油性成分のいずれもが用いら
れ得る。As the oily component, any of animal and plant and mineral natural oily components and synthetic oily components can be used.
【0062】動植物系の油性成分としては、例えば、ミ
ツロウ、水ロウ、カルナパロウ、キャンデリラウロ、カ
カオ脂、セチルアルコール(1−ヘキサデカノール)、
ステアリン酸アルキルエステル、ラノリン、オリーブ
油、椿油、ヒマシ油、綿実油、9−オクタデセン−1−
オール(オレイルアルコール)、オレイン酸、スクアラ
ン等が挙げられる。Examples of animal and plant oily components include beeswax, water wax, carnapa wax, candelillauro, cacao butter, cetyl alcohol (1-hexadecanol),
Stearic acid alkyl ester, lanolin, olive oil, camellia oil, castor oil, cottonseed oil, 9-octadecene-1-
Ole (oleyl alcohol), oleic acid, squalane and the like can be mentioned.
【0063】鉱物系の油性成分としては、固形パラフィ
ン、セレシン、マイクロクリスタリン、ワックス、ワセ
リン、流動パラフィン、シリコンオイル等が挙げられ
る。Examples of the mineral oil component include solid paraffin, ceresin, microcrystalline, wax, petrolatum, liquid paraffin, and silicone oil.
【0064】合成の油性成分としては、合成エステル
油、合成ポリエーテル油等が挙げられる。Examples of the synthetic oil component include synthetic ester oils and synthetic polyether oils.
【0065】上記油性成分は、例えば、約10〜80重
量%程度の量で含まれ得る。その範囲は、油性、弱油
性、中性等の化粧料のタイプによって異なり、適宜決定
され得る。The oil component may be contained, for example, in an amount of about 10 to 80% by weight. The range varies depending on the type of cosmetic, such as oiliness, weak oiliness, and neutrality, and can be determined as appropriate.
【0066】その他の成分として、本発明の基礎化粧品
は、柔軟剤(エモリアント剤)、角質軟化剤、可溶化
剤、緩衝剤、各種薬剤、香料、防腐剤、染料、褪色防止
剤、紫外線吸収剤、金属イオン封鎖剤等を適量含み得
る。As other components, the basic cosmetics of the present invention include softeners (emollients), keratin softeners, solubilizers, buffers, various chemicals, fragrances, preservatives, dyes, anti-fading agents, ultraviolet absorbers , A sequestering agent and the like in an appropriate amount.
【0067】柔軟剤(エモリアント剤)は、保湿、使用
感等に寄与し、例えば、エステル油、高級アルコール等
が挙げられる。The softener (emollient) contributes to moisturizing and feeling of use, and includes, for example, ester oils and higher alcohols.
【0068】角質軟化剤としては、水酸化カリウム、炭
酸カリウム等のアルカリ類が挙げられる。Examples of the keratin softener include alkalis such as potassium hydroxide and potassium carbonate.
【0069】乳化剤(可溶化剤、界面活性剤)として
は、ポリオキシエチレンオレイルエーテル、オクチルド
デカノール、親油性モノステアリン酸グリセリン、自己
乳化型プロピレングリコールモノステアレート、ポリオ
キシエチレンセチルエーテル、ポリオキシエチレンソル
ビタンモノラウリン酸エステル等が挙げられる。乳化
剤、例えばオクチルドデカノールは、通常約2〜8重量
%、好ましくは約3〜5重量%の量で添加され得る。Emulsifiers (solubilisers, surfactants) include polyoxyethylene oleyl ether, octyldodecanol, lipophilic glyceryl monostearate, self-emulsifying propylene glycol monostearate, polyoxyethylene cetyl ether, polyoxyethylene Ethylene sorbitan monolaurate and the like. Emulsifiers, such as octyldodecanol, can be added in amounts usually of about 2-8% by weight, preferably about 3-5% by weight.
【0070】薬剤としては、p−フェノールスルホン酸
亜鉛等の収斂剤、ベンザルコニウム塩酸塩等の殺菌剤、
ビタミン・アミノ酸誘導体等の栄養剤等が挙げられる。Examples of the drug include an astringent such as zinc p-phenolsulfonate; a bactericide such as benzalkonium hydrochloride;
Nutrients such as vitamin and amino acid derivatives.
【0071】緩衝剤(pH調整剤)としては、クエン酸
およびその塩等が挙げられる。Examples of the buffer (pH adjusting agent) include citric acid and salts thereof.
【0072】なお、化粧クリームには、通常、エモリエ
ントクリーム、マッサージクリーム、クレンジングクリ
ーム、メイクアップクリーム、サンスクリーンクリー
ム、ヘアクリーム、デオドラントクリーム、シェイビン
グクリーム、フェイスクリーム、ハンドクリーム、ボデ
ィークリーム等、用途、機能、塗布部位等の相違に基づ
く種々の称呼のものが含まれるが、本発明では、これら
全てを包含する。The cosmetic creams usually include emollient cream, massage cream, cleansing cream, makeup cream, sunscreen cream, hair cream, deodorant cream, shaving cream, face cream, hand cream, body cream, etc. Although various names based on differences in functions, application sites, and the like are included, the present invention includes all of these.
【0073】仕上げ化粧品(ファンデーション、口紅、
頬紅、おしろい等)への用途として、リポソームには、
上記水性成分の他に、顔料が含まれる。顔料としては、
例えば、酸化鉄、酸チタン、酸化亜鉛、タルク、セリサ
イト、カオリン、タール系色素のアルミニウムあるいは
バリウムレーキ、パール顔料の雲母チタン等の、有機お
よび無機の顔料が挙げられる。Finish cosmetics (foundation, lipstick,
Liposomes are used for
In addition to the aqueous component, a pigment is included. As a pigment,
Examples thereof include organic and inorganic pigments such as iron oxide, titanium oxide, zinc oxide, talc, sericite, kaolin, aluminum or barium lake as a tar pigment, and mica titanium as a pearl pigment.
【0074】そして、仕上げ化粧品には、リポソームの
他に、一般的に仕上げ化粧品に用いられる成分が含まれ
ていてもよい。例えば、上記油性成分、水性成分等を適
宜、選択し、適量用いることができる。The finished cosmetic may contain components generally used for finished cosmetics, in addition to liposomes. For example, the oil component, the aqueous component, and the like can be appropriately selected and used in an appropriate amount.
【0075】頭髪用化粧料としてはシャンプー、リン
ス、トリートメントまたは整髪料が挙げられる。シャン
プー、リンス、トリートメントまたは整髪料に養毛成分
あるいは育毛成分が含まれていてもよい。[0075] Cosmetic products for hair include shampoos, rinses, treatments and hair styling products. A shampoo, a rinse, a treatment or a hairdressing material may contain a hair-growing component or a hair-growing component.
【0076】頭髪用化粧料組成物には、通常頭髪用化粧
料に含まれる水性成分及び/または油性成分を含有する
リポソームが分散された組成物、並びに上記リポソーム
の他に、頭髪用化粧料に使用される各種成分が分散され
た組成物であってもよい。The hair cosmetic composition includes, in addition to the above-described liposomes, a composition in which liposomes containing an aqueous component and / or an oil component usually contained in hair cosmetics are dispersed. It may be a composition in which various components used are dispersed.
【0077】配合される成分としては、例えば、乳濁
剤、コンディショニング剤、アルコール、フケ取り剤、
殺菌剤、トニック剤、柔軟剤(エモリエント剤)、角質
軟化剤、粘液剤、キレート化剤、各種薬剤、香料、防腐
剤、染料、褪色防止剤、紫外線吸収剤、金属イオン封鎖
剤等が挙げられる。The components to be blended include, for example, emulsifiers, conditioning agents, alcohol, dandruff agents,
Disinfectants, tonics, softeners (emollients), keratin softeners, mucous agents, chelating agents, various chemicals, fragrances, preservatives, dyes, anti-fading agents, ultraviolet absorbers, sequestering agents, etc. .
【0078】粘液剤(増粘剤)は、保湿性、安定性、使
用感等に寄与し、具体的には、例えば、クインスシート
(クインスシードゴム)、トラガントガム、ペクチン、
アルギン酸塩、セルロース誘導体(例えば、カルボキシ
メチルセルロースナトリウム)、アクリル酸系ポリマ
ー、ビーガム、ポリビニルアルコールおよび電解質(例
えば、塩化ナトリウム、塩化カリウム)等が挙げられ
る。The mucous agent (thickener) contributes to moisturizing properties, stability, feeling of use, etc. Specifically, for example, quince sheet (quince seed gum), tragacanth gum, pectin,
Alginates, cellulose derivatives (for example, sodium carboxymethylcellulose), acrylic acid-based polymers, veegum, polyvinyl alcohol, and electrolytes (for example, sodium chloride, potassium chloride) and the like.
【0079】ハイドロトロープは、洗髪剤の低温安定
性、界面活性剤の溶解性向上に寄与する。例えば、殺菌
剤としても用いられるエタノール、プロピレングリコー
ル、保湿剤としても用いられるグリセリン等のアルコー
ル類、ポリオキシエチレンソルビタンモノラウレート、
ポリエチレングリコール脂肪酸エステル等の非イオン性
可溶化剤、ベンゼンスルホン酸ナトリウム、キシレンス
ルホン酸ナトリウム、および尿素等が挙げられる。The hydrotrope contributes to improving the low-temperature stability of the hair wash and the solubility of the surfactant. For example, ethanol used as a bactericide, propylene glycol, alcohols such as glycerin also used as a humectant, polyoxyethylene sorbitan monolaurate,
Examples include nonionic solubilizers such as polyethylene glycol fatty acid esters, sodium benzenesulfonate, sodium xylenesulfonate, and urea.
【0080】乳濁剤は、シャンプーを乳濁化し、高級
感、マイルド感、クリーム感の付与に寄与する。例え
ば、スチレンポリマー、ポリ酢酸ビニル等が挙げられ
る。ステアリン酸マグネシウム、エチレングリコールモ
ノステアレート、エチレングリコールジステアレート、
ステアリルアルコール、魚鱗箔、雲母チタン等は、真珠
光沢剤として使用され得る。Emulsifiers emulsify shampoos and contribute to imparting a luxurious, mild and creamy feel. For example, styrene polymer, polyvinyl acetate and the like can be mentioned. Magnesium stearate, ethylene glycol monostearate, ethylene glycol distearate,
Stearyl alcohol, fish scale foil, titanium mica and the like can be used as pearlescent agents.
【0081】コンディショニング剤は、櫛通り、ぱさつ
きの改善、髪のしなやかさ、まとまりやすさ、毛髪強化
等に寄与する。例えば、コラーゲンまたはその加水分解
物、アミノ酸、2−ピロリドン−5−カルボン酸ナトリ
ウム、ミルクカゼイン、卵アルブミン、レシチン、セラ
ミド、パンテノール(ビタミンB複合体)等の化学吸着
性のもの、ラノリンおよびその誘導体、スクワラン、流
動パラフィン、ワセリン、脂肪酸、高級アルコール、エ
ステル、シリコン油およびその誘導体、油脂(例えば、
ヒマシ油、オリーブ油)等の油性の物理吸着性のもの、
陽イオン変性セルロースエーテル誘導体、ポリビニルピ
ロリドン誘導体四級アンモニウム塩、塩化ジステアリル
ジメチルアンモニウムポリマー、アルキルポリエチレン
イミン等のイオン性吸着タイプの陽イオン性高分子等が
挙げられる。The conditioning agent contributes to combing, improvement of stiffness, suppleness of hair, ease of cohesion, strengthening of hair and the like. For example, collagen or its hydrolyzate, amino acids, sodium 2-pyrrolidone-5-carboxylate, milk casein, egg albumin, lecithin, ceramide, chemisorbents such as panthenol (vitamin B complex), lanolin and its derivatives Derivatives, squalane, liquid paraffin, petrolatum, fatty acids, higher alcohols, esters, silicone oil and its derivatives, fats and oils (for example,
Oil-based physical adsorptive substances such as castor oil and olive oil)
Examples thereof include cationically modified cellulose ether derivatives, quaternary ammonium salts of polyvinylpyrrolidone derivatives, distearyldimethylammonium chloride polymer, and ionic adsorption type cationic polymers such as alkyl polyethyleneimine.
【0082】アルコールは、清涼感、殺菌、配合成分の
溶解等に寄与する。例えば、エタノール、イソプロパノ
ール等が挙げられる。Alcohol contributes to a refreshing sensation, sterilization, dissolution of the components, and the like. For example, ethanol, isopropanol and the like can be mentioned.
【0083】フケ取り剤としては、例えば、硫黄、硫化
セレン、チンクピリジオン(Zpt)等の硫黄および硫
黄系化合物の他に、メントール類、トリクロサンハロカ
ルバン、アラントイン、およびサリチル酸等が挙げられ
る。Examples of the dandruff removing agent include, in addition to sulfur and sulfur compounds such as sulfur, selenium sulfide, tincpyridione (Zpt), menthols, triclosan halocarban, allantoin, and salicylic acid.
【0084】保湿剤は、角質層の保湿、使用感等に寄与
する。例えば、グリセリン、プロピレングリコール、ジ
プロピレングリコール、1,3−ブチレングリコール、
ポリエチレングリコール、多価アルコール、糖類、アミ
ノ酸類、およびソルビット等が挙げられる。The humectant contributes to moisturizing the stratum corneum, feeling of use, and the like. For example, glycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol,
Examples include polyethylene glycol, polyhydric alcohols, sugars, amino acids, and sorbitol.
【0085】柔軟剤(エモリアント剤)は、保湿、使用
感等に寄与し、例えば、エステル油、高級アルコール等
が挙げられる。The softener (emollient) contributes to moisturizing and feeling of use, and includes, for example, ester oils and higher alcohols.
【0086】角質軟化剤としては、水酸化カリウム、炭
酸カリウム等のアルカリ類が挙げられる。Examples of the keratin softener include alkalis such as potassium hydroxide and potassium carbonate.
【0087】薬剤としては、p−フェノールスルホン酸
亜鉛等の収斂剤、ベンザルコニウム塩酸塩等の殺菌剤、
ビタミン・アミノ酸誘導体等の栄養剤、紫外線吸収剤等
が挙げられる。Examples of the drug include an astringent such as zinc p-phenolsulfonate; a bactericide such as benzalkonium hydrochloride;
Nutrients such as vitamin / amino acid derivatives, ultraviolet absorbers and the like.
【0088】その他、緩衝剤(pH調整剤)が用いられ
る。例として、クエン酸およびその塩が挙げられる。In addition, a buffer (pH adjusting agent) is used. Examples include citric acid and its salts.
【0089】本発明のシャンプーおよびトリートメント
には、本発明のリポソームの他に、約1〜40重量%の
界面活性剤と、増泡剤、ハイドロトロープ(可溶化剤)
等を含んでいてもよい。In the shampoo and treatment of the present invention, in addition to the liposome of the present invention, about 1 to 40% by weight of a surfactant, a foaming agent, and a hydrotrope (solubiliser)
Etc. may be included.
【0090】界面活性剤としては、陰イオン性、陽イオ
ン性、両イオン性、非イオン性のいずれの界面活性剤で
も用いられ得る。界面活性剤は、約1〜40重量%の量
で含まれ得る。As the surfactant, any of anionic, cationic, amphoteric and nonionic surfactants can be used. Surfactants can be included in amounts of about 1-40% by weight.
【0091】陰イオン性界面活性剤としては、例えば、
アルキル硫酸塩(AS)、アルキルエーテル硫酸塩(A
ES)、α−オレフィンスルホン酸塩(AOS)、石
鹸、グリセリンモノアルキルエステルモノ硫酸塩、蛋白
・脂肪酸縮合物、アルキルリン酸エステル塩類等が挙げ
られる。Examples of the anionic surfactant include, for example,
Alkyl sulfate (AS), alkyl ether sulfate (A
ES), α-olefin sulfonate (AOS), soap, glycerin monoalkyl ester monosulfate, protein / fatty acid condensate, alkyl phosphate ester salts and the like.
【0092】陽イオン界面活性剤は、特に、ヘアリンス
の主成分としても用いられる。例えば、塩化アルキルト
リメチルアンモニウム、塩化ジアルキルジメチルアンモ
ニウム、塩化アルキルジメチルベンジルアンモニウム等
が挙げられる。[0092] Cationic surfactants are also used, in particular, as the main component of hair rinses. For example, alkyl trimethyl ammonium chloride, dialkyl dimethyl ammonium chloride, alkyl dimethyl benzyl ammonium chloride and the like can be mentioned.
【0093】両イオン界面活性剤としては、例えば、イ
ミダゾリン型、アルキルベタイン型、アルキルスルホン
ベタイン型等の界面活性剤等が挙げられる。Examples of the zwitterionic surfactant include imidazoline type, alkyl betaine type and alkyl sulfone betaine type surfactants.
【0094】非イオン性界面活性剤としては、例えば、
アルカノールアミド、アミンオキサイド等が挙げられ
る。Examples of the nonionic surfactant include, for example,
Alkanolamide, amine oxide and the like can be mentioned.
【0095】増泡剤は、シャンプー基材としての界面活
性剤の起泡性を高めるのに寄与し、脂肪酸アルカノール
アミド、脂肪酸、高級アルコール、水溶性高分子等が挙
げられる。The foaming agent contributes to enhancing the foaming property of the surfactant as a shampoo base material, and examples thereof include fatty acid alkanolamides, fatty acids, higher alcohols, and water-soluble polymers.
【0096】育毛剤、養毛剤としては、エタノール、女
性ホルモン、副腎皮質ホルモン、ビタミンB6、ビタミ
ンE、パントテン酸およびその誘導体、カンタリスチン
キ、トウガラシチンキ、ショウキョウチンキ、センブリ
エキス、セファランチン、ヒノキチオール、感光素、サ
リチル酸、レゾルシン、メントール、抗ヒスタミン剤、
グリチルリチン、塩化カルブロニウム、ベイラム、オー
ドキニン等が挙げられる。Examples of the hair restorer and the hair restorer include ethanol, female hormones, corticosteroids, vitamin B6, vitamin E, pantothenic acid and its derivatives, cantaritis tincture, capsicum tincture, ginger tincture, assembly extract, cepharanthin, hinokitiol, photosensitive Element, salicylic acid, resorcinol, menthol, antihistamine,
Glycyrrhizin, carburonium chloride, bayram, audocinin and the like can be mentioned.
【0097】なお、本発明の化粧料、シャンプーおよび
/またはトリートメント、ならびに整髪料の製造には、
公知の方法が使用され得る。The cosmetics, shampoos and / or treatments and hair stylings of the present invention are manufactured by
Known methods can be used.
【0098】[0098]
【実施例】以下、本発明を実施例を挙げて説明するが、
本発明はこの実施例により限定されるものではない。The present invention will be described below with reference to examples.
The present invention is not limited by this embodiment.
【0099】(本発明に用いる水の製造例)スリット間
隙幅2mm、水流流速約15m/分、磁力線強度1.2T
にて、純水および精製水をそれぞれ24時間循環させて
磁力線照射水を得た。得られた純水からの磁力線処理
水、精製水からの磁力線処理水および精製水の半値幅を
日本電子(株)製のJNM EX−270を用いて測定
した。半値幅を以下に示す。 純水からの磁力線処理水 56.3Hz 精製水からの磁力線処理水 83.7Hz 精製水 142.4Hz(Production example of water used in the present invention) Slit gap width 2 mm, water flow velocity about 15 m / min, magnetic field line intensity 1.2 T
, Pure water and purified water were respectively circulated for 24 hours to obtain magnetic field irradiation water. The half-value width of the magnetic-field-treated water from the obtained pure water, the magnetic-field-treated water from the purified water, and the purified water were measured using JNM EX-270 manufactured by JEOL Ltd. The half width is shown below. Magnetic line treated water from pure water 56.3 Hz Magnetic line treated water from purified water 83.7 Hz Purified water 142.4 Hz
【0100】(参考例:オレイン酸トリグリセライドの
分散性)純水および精製水からの磁力線処理水、並びに
精製水の各10mlにオレイン酸トリグリセライドをそれぞ
れ43.5mg添加し、128rpmで5分間振とうした後、直ちに
4ml採取し試料とする。各試料0.54mlをΦ5mmのNM
R試料管に採取して、内部標準として濃度10mM TSP-
d4重水溶液0.06mlを添加した。TSP-d4の最終濃度を
1mMとし1H-NMR測定を行った。この測定において、1H
-NMRスペクトルは、水による巨大な1H信号が不要であ
るため、1H−Homo Gated Decoupling(HMG)法を利用
して抑制し、128回の積算測定を行った。水中に分散し
たオレイン酸トリグリセライド濃度は、オレイン酸トリ
グリセライドのメチレン基の信号強度と内部標準である
TSP-d4のメチルプロトンの信号強度比から計算した。
なお、測定は日本電子(株)製JNM LA-400 FT-NMR Spec
trometerを用いて行った。(Reference Example: Dispersibility of Triglyceride Oleate) 43.5 mg of oleic acid triglyceride was added to each of 10 ml of water treated with magnetic field from purified water and purified water, and the mixture was shaken at 128 rpm for 5 minutes. Immediately collect 4 ml to make a sample. 0.54 ml of each sample is NM of Φ5mm
Samples were collected in an R sample tube and used as an internal standard at a concentration of 10 mM TSP-
It was added d 4 fold aqueous 0.06 ml. The final concentration of TSP-d 4 was then the 1 H-NMR measurement and 1 mM. In this measurement, 1 H
Since the NMR spectrum does not require a huge 1 H signal due to water, it was suppressed using the 1 H-Homo Gated Decoupling (HMG) method, and 128 integrated measurements were performed. The concentration of triglyceride oleate dispersed in water is the signal strength and internal standard of the methylene group of oleate triglyceride
It was calculated from the signal intensity ratio of the methyl protons of TSP-d 4.
The measurement was performed using JNM LA-400 FT-NMR Spec from JEOL Ltd.
This was performed using a trometer.
【0101】測定の結果、純水を磁気処理して得られた
水に分散しているオレイン酸トリグリセライドの相対強
度は、精製水の場合の相対強度の約2倍であることが分
かった。また、精製水からの磁力線処理水は、精製水の
場合の相対強度の約1.1倍であることも分かった。こ
の事実は、クラスターが小さい水の方が精製水よりトリ
オレイン酸の分散性に優れていることを示している。As a result of the measurement, it was found that the relative strength of triglyceride oleate dispersed in water obtained by magnetically treating pure water was about twice that of purified water. In addition, it was also found that the magnetic field line treated water from the purified water was about 1.1 times the relative intensity of the purified water. This fact indicates that water having smaller clusters has better dispersibility of trioleic acid than purified water.
【0102】(実施例1)製造例で得られた純水からの
磁力線処理水(半値幅:56.3Hz)を用いて、シャ
ンプー用のリポソームを作製した。比較例として、市販
の日本薬局方の精製水(半値幅:142.4Hz)を用
いた。 を混合し、みずほ工業株式会社製のマイクロフルイダイ
ザーにかけて、リポソームを作製し、大塚電子株式会社
製のダイナミック光散乱光度計(DLS−7000)を
用いて動的光散乱法により粒度分布を測定した。磁力線
処理水(半値幅:56.3Hz)および精製水(半値
幅:142.4Hz)を用いた場合の粒度分布は、それ
ぞれ、55nm(0.055μm)および112nm(0.112
μm)であった。磁力線処理水を用いたリポソームの平
均粒径は、精製水を用いたリポソームの約1/2であ
り、用いる水によって、リポソームの平均粒径に大きな
差異が見られた。Example 1 Liposomes for shampoo were prepared using magnetically treated water (half width: 56.3 Hz) from pure water obtained in Production Example. As a comparative example, commercially available purified water (half width: 142.4 Hz) of the Japanese Pharmacopoeia was used. Were mixed and passed through a microfluidizer manufactured by Mizuho Industry Co., Ltd. to produce liposomes, and the particle size distribution was measured by a dynamic light scattering method using a dynamic light scattering photometer (DLS-7000) manufactured by Otsuka Electronics Co., Ltd. . The particle size distributions when using magnetic line-treated water (half width: 56.3 Hz) and purified water (half width: 142.4 Hz) were 55 nm (0.055 μm) and 112 nm (0.112 μm), respectively.
μm). The average particle size of the liposomes using magnetic field-treated water was about half that of the liposomes using purified water, and a large difference was found in the average particle size of the liposomes depending on the water used.
【0103】(実施例2:リポソームを含むシャンプー
組成物の作製)実施例1で得られたリポソーム原液をそ
れぞれ用いて、以下の組成のシャンプー組成物を作製し
た。なお、単位は重量%である。 リポソーム原液 5% アルキルエーテル硫酸ナトリウム 16% ラウリル酸ジエタノールアミド 4% プロピレングリコール 2% 防腐剤、色素、香料 微量 水 残量 磁力線処理水で作製したシャンプーは、精製水を用いて
作製したシャンプーに比べて、髪がしっとりとしてお
り、使用感もよかった。(Example 2: Preparation of shampoo composition containing liposome) A shampoo composition having the following composition was prepared using each of the liposome stock solutions obtained in Example 1. The unit is% by weight. Liposome stock solution 5% Sodium alkyl ether sulfate 16% Lauryl acid diethanolamide 4% Propylene glycol 2% Preservatives, dyes, fragrances Trace amount of water Remaining shampoo made with magnetically treated water compared to shampoo made with purified water The hair was moist and the usability was good.
【0104】[0104]
【発明の効果】半値幅が90Hz以下の水を用いて作製
されたリポソームの平均粒径は、通常の水を用いて作製
されたリポソームの平均粒径よりも小さく、医薬組成物
に用いられた場合、体内へより速く吸収され、標的器官
や組織の周囲に高濃度の医薬品を伝達でき、徐放性とあ
いまって、高い薬理効果が期待できる。The average particle size of liposomes prepared using water having a half width of 90 Hz or less is smaller than the average particle size of liposomes prepared using ordinary water, and was used in pharmaceutical compositions. In such a case, the drug can be absorbed into the body faster, and a high concentration of the drug can be transmitted to the periphery of the target organ or tissue.
【0105】また、化粧品組成物、育毛剤組成物、ある
いは養毛剤組成物に用いた場合も、皮膚あるいは毛髪組
織への親和性に優れるため、例えば、保湿成分、育毛成
分、あるいは養毛成分等が皮膚角質層、毛髪等に付着、
進入しやすくなり、徐放性とあいまって、高い効果が期
待できる。Also, when used in a cosmetic composition, a hair restorer composition, or a hair restorer composition, since it has excellent affinity for skin or hair tissue, for example, a moisturizing component, a hair restorer component, a hair restorer component, etc. Attached to skin stratum corneum, hair, etc.
It is easy to enter, and combined with sustained release, a high effect can be expected.
【0106】特に、半値幅が60Hz以下の水を用いた
場合、油脂類を通常の水の1.5倍以上も分散させる能
力を有することから、リポソーム内に、より多量の医
薬、化粧料、育毛剤あるいは養毛剤を保持することがで
きるので、さらに高い効果が期待できる。In particular, when water having a half width of 60 Hz or less is used, since it has the ability to disperse fats and oils 1.5 times or more of ordinary water, a larger amount of drugs, cosmetics, Since a hair restorer or a hair restorer can be retained, a higher effect can be expected.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 7/075 C02F 1/48 A C02F 1/48 B01J 13/02 Z Fターム(参考) 4C076 AA19 AA95 BB01 BB13 BB15 BB16 BB22 BB24 BB25 BB27 BB28 BB29 BB30 BB31 DD34 DD38 DD50 DD59 DD63F EE43 FF16 GG21 4C083 AB051 AC022 AC122 AC432 AC542 AC642 AC662 AC782 AC901 AC902 CC01 CC04 CC05 CC12 CC32 CC33 CC37 CC38 CC39 DD31 DD45 EE22 4D061 DA03 DB06 EA18 EC05 FA08 4G005 AA07 AB30 BB01 DB08X DB22X DB23X DC18X DC56Y EA03 ──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 7/075 C02F 1/48 A C02F 1/48 B01J 13/02 Z F-term (Reference) 4C076 AA19 AA95 BB01 BB13 BB15 BB16 BB22 BB24 BB25 BB27 BB28 BB29 BB30 BB31 DD34 DD38 DD50 DD59 DD63F EE43 FF16 GG21 4C083 AB051 AC022 AC122 AC432 AC542 AC642 AC662 AC782 AC901 AC902 CC01 CC04 CC05 CC12 CC32. AB30 BB01 DB08X DB22X DB23X DC18X DC56Y EA03
Claims (15)
Hz以下の水と目的物質と両親媒性化合物とを混合して
得られる微小な粒径を有するリポソームであって、該リ
ポソームの平均粒径が、通常の水を用いて製造されたリ
ポソームの平均粒径よりも小さいリポソーム。The half-value width of the 17 O-NMR signal is 90.
Hz and a liposome having a fine particle diameter obtained by mixing water, a target substance, and an amphiphilic compound, wherein the average particle diameter of the liposome is the average of liposomes produced using ordinary water. Liposomes smaller than particle size.
請求項1に記載のリポソーム。2. The method according to claim 1, wherein the amphiphilic compound is a phospholipid.
The liposome according to claim 1.
2に記載のリポソーム。3. The liposome according to claim 2, wherein the phospholipid is lecithin.
Hz以下の水と目的成分と両親媒性化合物とを混合する
工程を含む、微小な粒径を有するリポソームの製造方
法。4. The half-value width of a 17 O-NMR signal is 90.
A method for producing a liposome having a fine particle diameter, comprising a step of mixing water, a target component, and an amphiphilic compound at a frequency of not more than Hz.
幅が60Hz以下である、請求項4に記載の製造方法。5. The method according to claim 4, wherein the half-width of the 17 O-NMR signal of water is 60 Hz or less.
である、請求項4または5に記載の製造方法。6. The method according to claim 4, wherein the water is water obtained by magnetizing pure water.
請求項4ないし6いずれかの項に記載の製造方法。7. The method according to claim 1, wherein the amphiphilic compound is a phospholipid.
The method according to claim 4.
7に記載の製造方法。8. The method according to claim 7, wherein the phospholipid is lecithin.
Hz以下の水と目的物質と両親媒性化合物とを混合して
得られる微小な粒径を有するリポソームを含有する組成
物。9. The half-value width of a 17 O-NMR signal is 90.
A composition containing a liposome having a fine particle diameter obtained by mixing water at a frequency of not more than Hz, a target substance, and an amphiphilic compound.
る、請求項9に記載の組成物。10. The composition according to claim 9, wherein said amphiphilic compound is a phospholipid.
項10に記載の組成物。11. The composition according to claim 10, wherein said phospholipid is lecithin.
または養毛剤であり、前記組成物が医薬組成物、化粧品
組成物、育毛組成物または養毛組成物である請求項9な
いし11いずれかの項に記載の組成物。12. The composition according to claim 9, wherein the target substance is a drug, a cosmetic, a hair restorer or a hair restorer, and the composition is a pharmaceutical composition, a cosmetic composition, a hair restorer or a hair restorer. The composition according to Item.
化粧水、乳液、美容液、ファンデーション、シャンプ
ー、リンス、トリートメントまたは整髪料である請求項
12に記載の組成物。13. The cosmetic composition, wherein the cosmetic composition comprises
The composition according to claim 12, which is a lotion, an emulsion, a serum, a foundation, a shampoo, a rinse, a treatment or a hairdressing agent.
ントまたは整髪料が養毛成分及び/または育毛成分を含
んでいる、請求項13に記載の組成物。14. The composition according to claim 13, wherein the shampoo, rinse, treatment or hair styling comprises a hair-growing component and / or a hair-growing component.
用、体表適用および血管内または組織内投与の投与・適
用形態に適合した組成物である、請求項12に記載の組
成物。15. The composition according to claim 12, wherein the pharmaceutical composition is a composition suitable for an administration / application form for oral administration, mucosal application, body surface application, and intravascular or intratissue administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11028910A JP2000229815A (en) | 1999-02-05 | 1999-02-05 | Liposomes and their use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11028910A JP2000229815A (en) | 1999-02-05 | 1999-02-05 | Liposomes and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000229815A true JP2000229815A (en) | 2000-08-22 |
Family
ID=12261569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11028910A Pending JP2000229815A (en) | 1999-02-05 | 1999-02-05 | Liposomes and their use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000229815A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002212106A (en) * | 2000-12-20 | 2002-07-31 | Biozone Lab Inc | Self forming, thermodynamically stable liposome and its application |
| JP2003001097A (en) * | 2001-06-22 | 2003-01-07 | Techno Network Shikoku Co Ltd | Method of making nanosize lipid vesicle |
| JP2003342171A (en) * | 2002-05-23 | 2003-12-03 | Usv Ltd | Compositions for administration of disulanol |
| WO2004019966A1 (en) * | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein solution preparation |
| JP2009120584A (en) * | 2007-09-26 | 2009-06-04 | Lvmh Recherche | Cosmetic composition in form of emulsion comprising continuous aqueous phase and dispersed fatty phase and preparation method thereof |
| WO2008131936A3 (en) * | 2007-04-25 | 2009-10-01 | Akuatech S.R.L. | Highly stable electrolytic water with reduced nmr half line width |
| JP2011057668A (en) * | 2009-08-12 | 2011-03-24 | Taisho Pharmaceutical Co Ltd | Liposome preparation |
| US8277634B2 (en) | 2005-10-28 | 2012-10-02 | Apr Nanotechnologies S.A. | Electrolytic water treatment device having sintered nanoparticle coated electrode and method for making acid or basic water therewith |
| US8691289B2 (en) | 2009-06-17 | 2014-04-08 | Apr Nanotechnologies S.A. | Methods of treating outer eye disorders using high ORP acid water and compositions thereof |
| JP2019042679A (en) * | 2017-09-04 | 2019-03-22 | 一丸ファルコス株式会社 | pH sensitive liposome |
-
1999
- 1999-02-05 JP JP11028910A patent/JP2000229815A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002212106A (en) * | 2000-12-20 | 2002-07-31 | Biozone Lab Inc | Self forming, thermodynamically stable liposome and its application |
| JP2003001097A (en) * | 2001-06-22 | 2003-01-07 | Techno Network Shikoku Co Ltd | Method of making nanosize lipid vesicle |
| JP2003342171A (en) * | 2002-05-23 | 2003-12-03 | Usv Ltd | Compositions for administration of disulanol |
| WO2004019966A1 (en) * | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein solution preparation |
| US8277634B2 (en) | 2005-10-28 | 2012-10-02 | Apr Nanotechnologies S.A. | Electrolytic water treatment device having sintered nanoparticle coated electrode and method for making acid or basic water therewith |
| US9404192B2 (en) | 2007-04-25 | 2016-08-02 | Apr Nanotechnologies S.A. | Highly stable electrolytic water with reduced NMR half line width |
| WO2008131936A3 (en) * | 2007-04-25 | 2009-10-01 | Akuatech S.R.L. | Highly stable electrolytic water with reduced nmr half line width |
| US9889153B2 (en) | 2007-04-25 | 2018-02-13 | Apr Nanotechnologies S.A. | Highly stable electrolytic water with reduced NMR half line width |
| AU2008243353B2 (en) * | 2007-04-25 | 2014-02-06 | Akuatech S.R.L. | Highly stable electrolytic water with reduced NMR half line width |
| US8709495B2 (en) | 2007-04-25 | 2014-04-29 | Apr Nanotechnologies S.A. | Highly stable electrolytic water with reduced NMR half line width |
| JP2009120584A (en) * | 2007-09-26 | 2009-06-04 | Lvmh Recherche | Cosmetic composition in form of emulsion comprising continuous aqueous phase and dispersed fatty phase and preparation method thereof |
| US8691289B2 (en) | 2009-06-17 | 2014-04-08 | Apr Nanotechnologies S.A. | Methods of treating outer eye disorders using high ORP acid water and compositions thereof |
| JP2011057668A (en) * | 2009-08-12 | 2011-03-24 | Taisho Pharmaceutical Co Ltd | Liposome preparation |
| JP2019042679A (en) * | 2017-09-04 | 2019-03-22 | 一丸ファルコス株式会社 | pH sensitive liposome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5191988B2 (en) | Nanoliposomes using esterified lecithin, method for producing the same, and composition for preventing or treating skin diseases comprising the same | |
| JP4203394B2 (en) | Micronized liposomes containing a high concentration of triterpenoid and method for producing the same | |
| JP3955090B2 (en) | Formulation for improving blood supply containing hard magnetic particles | |
| JP6131194B2 (en) | Empty nanoparticle composition and use thereof for treating dermatological symptoms | |
| JPS6156016B2 (en) | ||
| TW200817039A (en) | Compositions and methods for skin lightening | |
| US12364654B2 (en) | Method for manufacturing spicule coated with diamond and ingredients effective for skin improvement, and diamond spicule cosmetic composition including the same | |
| JPH01163110A (en) | Preventive for aging of skin | |
| JP2000229815A (en) | Liposomes and their use | |
| JP2983517B2 (en) | Novel salicylic acid derivatives and their use in cosmetic and / or dermatological compositions | |
| JP2005082600A (en) | How to treat skin symptoms | |
| JP2013533308A (en) | Pharmaceutical or cosmetic composition comprising nicotinic acid adenine dinucleotide phosphate or a derivative thereof | |
| JPH11333498A (en) | Production of pure water | |
| CN108324581B (en) | Liposome, liposome body fluid and cosmetic, and method for producing the same | |
| JPH11128951A (en) | Water with excellent dispersibility of fats and oils | |
| JP5669437B2 (en) | Composition | |
| JPH05262635A (en) | Dermatic external preparation | |
| JP2006028026A (en) | Hair-growing agent | |
| Nayak et al. | Ethosomes for dermal and transdermal drug delivery systems | |
| JP2011241166A5 (en) | ||
| JPH11322573A (en) | Structural water for giving increased moisture | |
| JP2021038178A (en) | Vesicle composition, and cosmetics and skin external preparations comprising the same | |
| JP2009234986A (en) | Skin external preparation containing synergistic effect water | |
| JPH10175868A (en) | Water (of chinese medicine idea) improving composition | |
| JP4931369B2 (en) | Liposomes and therapeutic compositions containing the same |